Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 44, Issue 3, 2009, Pages 366-374

  Ekstedt, Mattias ^a   Franzén, Lennart E ^b   Holmqvist, Marika ^a   Bendtsen, Preben ^a   Mathiesen, Ulrik L ^c   Bodemar, Göran ^a   Kechagias, Stergios ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Aleris Medilab ^*  (Sweden)

^c Department of Internal Medicine   (Sweden)

Author keywords

Alcoholic liver disease; Fatty liver; Histopathology; Liver fibrosis; Non alcoholic fatty liver disease

Indexed keywords

LIVER ENZYME;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUESTIONNAIRE;

ALANINE TRANSAMINASE; ALCOHOL DRINKING; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 61649123826     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520802555991     Document Type: Article

References (35)

1. Andreasson S, Allebeck P, Romelsjö A. Alcohol and mortality among young men: longitudinal study of Swedish conscripts. Br Med J 1988;296:1021-5.
2. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW Jr, et al. Alcohol consumption and mortality among middle-aged and elderly US adults. N Engl J Med 1997;337:1705-14.
3. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. Arch Intern Med 2006;166:2437-45.
4. Miller DJ, Ishimaru H, Klatskin G. Non-alcoholic liver disease mimicking alcoholic hepatitis and cirrhosis [abstract]. Gastroenterology 1979;77:A27.
5. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-6.
6. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434.
7. AGA technical review in nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705-25.
8. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
9. Suzuki A, Angulo P, St Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am J Gastroenterol 2007;102:1912-9.
10. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
11. Farrell G, Larter C. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.
12. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9.
13. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat 2002;9:235-41.
14. Mathiesen UL, Franzen LE, Fryden A, Foberg U, Bodemar G. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 1999;34:85-91.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
16. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37:1202-19.
17. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDITC): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med 1998;158:1789-95.
18. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggianni F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000;23:57-63.
19. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
20. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
21. Merriman RB, Ferrell LD, Patti MG,Weston SR, Pabst MS, Aouizerat BE, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006;44:874-80.
22. Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russel M. Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related. Am J Gastroenterol 2004;99:76-81.
23. Fiellin DA, Reid MC, O'Connor PG. Outpatient management of patients with alcohol problems. Ann Intern Med 2000;133:815-27.
24. Romelsjo A, Leifman H, Nystrom S. A comparative study of two methods for the measurement of alcohol consumption in the general population. Int J Epidemiol 1995;24:929-36.
25. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-8.
26. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 2005;3:1260-8.
27. Bell RA, Mayer-Davis EJ, Martin MA, D'Agostino RB Jr, Haffner SM. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study. Diabetes Care 2000;23:1630-6.
28. Zein C, Unalp A, Colvin R, McCullough AJ. Advanced fibrosis in NAFLD is associated with lifetime alcohol use, diabetes, and age but not with lifetime cigarette smoking [abstract]. Hepatology 2007;46:739A.
29. Day CP. From fat to inflammation. Gastroenterology 2006;130:207-10.
30. Kojima H, Sakurai S, Uemura M, Takekawa T, Morimoto H, Tamagawa Y, et al. Difference and similarity between non-alcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res ;:S 2005;29:259S-63.
31. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004;36:511-29.
32. Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, et al. Relationship between in vivo chlorzoxazone hydroxylation, hepatic cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res 2006;34:57-63.
33. Becker U, Deis A, Sorensen TI, Gronbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996;23:1025-9.
34. Bellentani S, Tiribelli C, Saccoccio G, Sodde M, Fratti N, De Martin, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994;20:1442-9.
35. Loria P, Lonardo A, Carulli N. Should non-alcoholic fatty liver disease be renamed? Dig Dis 2005;23:72-82.